TomoTherapy — Merger or Acquisition (March 2011)
29 slides from TomoTherapy's merger presentation, Mar 30, 2011
Slide 1: Accuray Incorporated, Euan S. Thomson, President and CEO
Accuray Incorporated Euan S. Thomson, Ph.D. President and CEO March 29, 2011
Slide 2: Forward-looking Statement Safe Harbor Statement
Forward-looking Statement Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry and the transaction between Accuray and TomoTherapy. Except for the historical inform
Slide 3: Accuray | TomoTherapy Deal Summary
Accuray | TomoTherapy Deal Summary
Slide 4: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialty Significant increase in global presence Financial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 5: Increased Global Presence
Increased Global Presence Worldwide Install Base 572 Systems Installed** Worldwide Accuray TomoTherapy Americas EIMEA Japan APAC Accuray Post Transaction 222 Systems Installed* 350 Systems Installed** *Installed as of December 31, 2010 **Shipped and/or installed as of February 17, 2011
Slide 6: Accuray Incorporated
Accuray Incorporated 200+ systems installed 100,000+ patients treated 75+ issued patents *as of December 31, 2010
Slide 7: TomoTherapy Incorporated
TomoTherapy Incorporated Data provided by TomoTherapy 350 systems** 110,000+ patients treated 130+ issued patents **Shipped and/or installed as of February 17, 2011 *as of December 31, 2010
Slide 8: Summary Corporate Metrics
Summary Corporate Metrics Metric Accuray TomoTherapy Revenue (CY2010) $206.1M $195.4M Net Income (CY2010) $6.8M ($29.9M) Expected Gross Operational Synergies Approx. $25M per year Product Backlog (Dec. 31, 2010) $170M* $133M** Installed Base 222 (12/31/10) 350*** (2/17/11) *Based on Accuray backlog
Slide 9: Deal Terms
Deal Terms TomoTherapy shareholders to receive $4.80 per share* in cash and stock $3.15 in cash 0.1648 shares of Accuray stock ($1.65) Expected to be accretive to Accuray’s EPS in its fiscal year beginning July 1, 2012 Approved by both companies’ Board of Directors Anticipated to close in Q2 or earl
Slide 10: CyberKnife Robotic Radiosurgery System
CyberKnife® Robotic Radiosurgery System
Slide 11: CyberKnife Robotic Radiosurgery System
CyberKnife® Robotic Radiosurgery System INTRACRANIAL RADIOSURGERY Well established, proven technique EXTRACRANIAL RADIOSURGERY Expanding discipline Is targeted toward a new group of patients RADIOSURGERY Use of a high dose of radiation to ablate a tumor as an alternative to surgery
Slide 12: CyberKnife Treatments
CyberKnife® Treatments
Slide 13: CyberKnife Treatments
cs CyberKnife® Treatments
Slide 14: CyberKnife US Market Opportunity
Prostate 136,000 patients per year CyberKnife® US Market Opportunity *primary and metastatic Treatable subset based on annual incidence data reported by the American Cancer Society and collected from published literature 84,000* patients per year Brain 70,000* patients per year Spine 380,000* patien
Slide 15: CyberKnife Radiosurgery Market Acceptance
Liver CyberKnife® Radiosurgery Market Acceptance Patient Treatments Time Intracranial Inoperable Lung Prostate Partial Breast Operable Lung Spine
Slide 16: Clinical Development: Worldwide Patient Treatments
Clinical Development Worldwide Patient Treatments This data includes estimates. If we are missing data from a site for one month, we take the number of patients treated in the previous month as an estimate for the missing month. If we are missing data from a site for a quarter (3 months), we take th
Slide 17: Corporate Development: Worldwide CyberKnife Installed Base
Corporate Development Worldwide CyberKnife® Installed Base YTD: 222 CyberKnife® Systems Installed Worldwide* *as of September 30, 2010
Slide 18: Accuray Record of Achievement
Accuray Record of Achievement Consistent record of technology innovation Regular upgrades support premium service programs New CyberKnife® platforms support stronger pricing Proven ability to drive market acceptance New products New clinical capabilities Profitability Product gross profit margin (>6
Slide 19: TomoHD: Clinical Market and Positioning
TomoHD: Clinical Market and Positioning
Slide 20: Objectives of State of the Art Modern RT
Objectives of State of the Art Modern RT Image Guidance (IGRT) Alignment accuracy Smaller margins Intensity Modulation (IMRT) Dose where it is needed Reduction of dose to critical structures
Slide 21: Evolution of Gantry Based Technology
Evolution of Gantry Based Technology Technology add-ons to 60 year old architecture Verification Images Multi-Leaf Collimator (MLC) Cone Beam CT (CBCT) Rotational treatment Incremental complexity Multiple independent systems Complex quality assurance Multi-step work flow When all capabilities are us
Slide 22: TomoTherapy's Revolutionary Architecture
TomoTherapy’s Revolutionary Architecture Unique IMRT/IGRT Platform “Voxel by Voxel” intensity modulation Radiation dose delivered independently to each volume element Fully integrated image guidance CT geometry optimal for 3D imaging “Plug and play” best in class solution Most sophisticated treatmen
Slide 23: TomoHD Extends Range of Clinical Applications
TomoHD Extends Range of Clinical Applications TomoHD allows for advanced treatment plans of wide field regions while sculpting dose, creating complex dose patterns that minimize normal tissue included in the treatment field
Slide 24: Seamless Full Body Treatment
Seamless Full Body Treatment
Slide 25: Seamless Full Body Treatment
Seamless Full Body Treatment Helical architecture enables continuous treatments along entire length of the body
Slide 26: Summary
Summary
Slide 27: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialty Significant increase in global presence Financial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 28: Q&A
Q&A
Slide 29: Accuray Incorporated, Euan S. Thomson, President and CEO
Accuray Incorporated Euan S. Thomson, Ph.D. President and CEO March 29, 2011